S'abonner

Door-to-Balloon Times in Hospitals Within the Get-With-The-Guidelines Registry After Initiation of the Door-to-Balloon (D2B) Alliance - 13/08/11

Doi : 10.1016/j.amjcard.2008.12.030 
Brahmajee K. Nallamothu, MD, MPH a, , Harlan M. Krumholz, MD, SM b, Eric D. Peterson, MD, MPH c, Wenqin Pan, PhD c, Elizabeth Bradley, PhD b, Amy F. Stern, MHS d, Frederick A. Masoudi, MD, MSPH e, David M. Janicke, MD f, Adrian F. Hernandez, MD, MHS b, Christopher P. Cannon, MD g, Gregg C. Fonarow, MD h

D2B Alliance and the American Heart Association Get-With-The-Guidelines Investigators

a Ann Arbor VA Medical Center, Ann Arbor, Michigan 
b Department of Epidemiology and Public Health and the Robert Wood Johnson Clinical Scholars Program, Department of Medicine, Yale University School of Medicine, New Haven, Connecticut 
c Duke Clinical Research Institute and Duke University Medical Center, Durham, North Carolina 
d National Quality Forum, Washington, DC 
e Department of Medicine, University of Colorado Health Sciences Center and Denver Health Medical Center, Denver, Colorado 
f State University of New York at Buffalo School of Medicine and Biomedical Sciences, Buffalo, New York 
g Brigham and Women's Hospital, Boston, Massachusetts 
h UCLA Medical Center, Los Angeles, California 

Corresponding author: Tel: 734-845-3054; fax: 734-214-0691

Résumé

To improve hospital performance in door-to-balloon (DTB) times nationally, the American College of Cardiology D2B Alliance recently enrolled approximately 1,000 hospitals that perform percutaneous coronary intervention (PCI) across the United States in a large national quality improvement effort. We evaluated recent changes in DTB times in hospitals within the Get-With-The-Guidelines (GWTG) Coronary Artery Disease (CAD) program, a partner in the D2B Alliance. Within GWTG-CAD participating hospitals, we studied DTB in nontransferred patients with ST-elevation myocardial infarction treated with primary PCI from July 2006 to March 2008. We evaluated the percentage of patients treated within 90 minutes and used multivariable models with generalized estimating equations to examine trends over time after accounting for changes in patients' characteristics. A total of 5,801 patients at 167 hospitals were included in our analysis, with 3,567 patients at 98 hospitals that joined the D2B Alliance. From July to September 2006, 54.1% of patients received primary PCI within 90 minutes. This number increased significantly during the study period: 335 (74.1%) of 452 patients at GWTG-CAD participating hospitals were treated within 90 minutes from January to March 2008, including 229 of 304 patients (75.3%) treated at hospitals that joined the D2B Alliance and 106 of 148 patients (71.6%) treated at other GWTG-CAD participating hospitals (p <0.001 for all comparisons over time). No statistically significant differences were noted in the rate of change between hospitals that joined the D2B Alliance and other GWTG-CAD participating hospitals. In conclusion, the percentage of patients treated with 90 minutes has dramatically increased at hospitals participating within the GWTG-CAD program, coinciding with the launch of the D2B Alliance. These improvements were broad and not limited to hospitals that joined the D2B Alliance.

Le texte complet de cet article est disponible en PDF.

Plan


© 2009  Publié par Elsevier Masson SAS.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 103 - N° 8

P. 1051-1055 - avril 2009 Retour au numéro
Article précédent Article précédent
  • Usefulness of Echocardiographic Assessment of Cardiac and Ascending Aorta Calcific Deposits to Predict Coronary Artery Calcium and Presence and Severity of Obstructive Coronary Artery Disease
  • Gaetano Nucifora, Joanne D. Schuijf, Jacob M. van Werkhoven, J. Wouter Jukema, Nina Ajmone Marsan, Eduard R. Holman, Ernst E. van der Wall, Jeroen J. Bax
| Article suivant Article suivant
  • Seasonal Variation in Lipids in Patients Following Acute Coronary Syndrome on Fixed Doses of Pravastatin (40 mg) or Atorvastatin (80 mg) (from the Pravastatin or Atorvastatin Evaluation and Infection Therapy–Thrombolysis In Myocardial Infarction 22 [PROVE IT-TIMI 22] Study)
  • Patricia Tung, Stephen D. Wiviott, Christopher P. Cannon, Sabina A. Murphy, Carolyn H. McCabe, C. Michael Gibson

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.